S&P 500 Healthcare Sector SEC Filings — May 29, 2026

29-05-2026

News Corp filed an 8-K on May 29, 2026, disclosing that it has provided daily transaction disclosures to the Australian Securities Exchange (ASX) under its existing $1 billion stock repurchase program. The filing includes forward-looking statements regarding the company's intent to repurchase Class A and Class B common stock from time to time, subject to market conditions and other factors. No specific financial results or material changes were reported in this filing.

• · The repurchase program authorizes up to $1 billion in aggregate of Class A and Class B common stock.
• · The company is required to provide daily transaction disclosures to the ASX under ASX rules.
• · The filing includes forward-looking statements subject to risks such as market price changes, general market conditions, securities laws, and alternative investment opportunities.
• · The report was signed by Michael L. Bunder, Senior Vice President, Deputy General Counsel and Corporate Secretary.

29-05-2026

Aptose Biosciences Inc. filed an 8-K on May 29, 2026, to disclose a press release under Regulation FD. The filing does not contain any financial results or material quantitative data, only the issuance of the press release itself.

• · The press release was issued on May 29, 2026, and is attached as Exhibit 99.1.
• · The filing is made under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• · The registrant is a Canadian corporation with principal executive offices in Toronto, Ontario.

29-05-2026

New Mountain Net Lease Trust declared monthly distributions for five classes of common shares on May 29, 2026, with a gross distribution of $0.1546 per share across all classes. Net distributions vary by class due to differing management fees, ranging from $0.1336 (Class I) to $0.1546 (Class E). The distributions are payable on June 8, 2026, to holders of record as of May 29, 2026.

• · Shareholder servicing fee is $0.00 for all classes.
• · No management fee is charged on Class E shares, resulting in the highest net distribution of $0.1546 per share.
• · Class I carries the highest management fee at $0.0210 per share.

29-05-2026

Pacific Coast Oil Trust announced no cash distribution for March 2026 due to a net profits deficit, with cumulative deficits of $11.7M for Developed Properties and $65,000 for Remaining Properties. The Trust faces ongoing litigation, including a derivative lawsuit against the Trustee and a whistleblower suit against PCEC, and its dissolution is mandated because annual cash proceeds from net profits interests were below $2.0M for 2020 and 2021. While average realized oil prices improved significantly month-over-month (Developed: $84.94/boe vs $53.14/boe; Remaining: $84.12/boe vs $51.75/boe), the Trust's debt to PCEC reached $13.7M, and distributions to unitholders remain extremely remote.

• · Crude oil sales volumes represented 99% of sales volumes for Developed Properties and 100% for Remaining Properties in March 2026.
• · A derivative lawsuit was filed on May 20, 2026, against the Trustee by Shipyard Capital, LP and others, alleging breach of contract, breach of fiduciary duty, gross negligence, willful misconduct, and negligent misrepresentation related to ARO deductions.
• · The whistleblower lawsuit (Brendan Potyondy v. PCEC) is proceeding after PCEC's motion for summary judgment was granted in part and denied in part on April 17, 2026; punitive damages are barred.
• · The Trust's dissolution is mandated because annual cash proceeds from net profits interests were below $2.0 million for both 2020 and 2021.
• · PCEC expects to continue making monthly accretion adjustments to ARO going forward.
• · Proceeds from any sale of Trust assets in dissolution will first repay amounts drawn from the letter of credit and borrowed from PCEC, with any remainder to unitholders; no net proceeds may remain for unitholders.

29-05-2026

Enveric Biosciences held its 2026 Annual Meeting on May 28, 2026, with 52.54% of outstanding shares represented. Stockholders approved the election of six directors, the Say-on-Pay proposal, a reverse stock split (1-for-5 to 1-for-15), and auditor ratification. However, the proposal to increase authorized common stock from 100,000,000 to 5,000,000,000 shares was voted down, with 555,147 votes against versus 427,158 for. The Board also adopted new forms of RSU and RSA agreements under the 2020 Long-Term Incentive Plan for future grants to executives and directors.

• · The Authorized Stock Increase Proposal was rejected: 427,158 for, 555,147 against, 9,523 abstentions.
• · The Reverse Stock Split Proposal passed with 793,344 for, 190,175 against, 8,309 abstentions.
• · The Say-on-Pay Proposal passed with 569,552 for, 26,884 against, 5,297 abstentions.
• · Auditor Ratification passed overwhelmingly: 960,728 for, 19,347 against, 11,753 abstentions.
• · All six director nominees were elected; broker non-votes were 390,095 for each nominee.
• · The new RSU Agreement provides for 4-year time-based vesting (25% on first anniversary, then monthly installments) and full acceleration upon change in control.
• · The new RSA Agreement provides for time-based vesting on a specified date with forfeiture of unvested shares upon termination.

29-05-2026

Invesco Commercial Real Estate Finance Trust, Inc. declared monthly distributions of $0.1600 per share for all seven classes of common stock for May 2026, payable on June 12, 2026 to stockholders of record as of May 31, 2026. Net distributions range from $0.1420 (Class S-1 after servicing fee) to $0.1600 (Classes D, I, E, F with no servicing fee). The gross distribution amount is uniform across all classes, with no period-over-period comparison provided in this filing.

• · Each class receives the same gross distribution of $0.1600 per share, but net amounts differ due to stockholder servicing fees.
• · Class S-1 has the lowest net distribution at $0.1420 per share due to the highest servicing fee of $0.0180.
• · Classes D, I, E, and F have no servicing fee, resulting in a full net distribution of $0.1600 per share.
• · Distributions are payable in cash or reinvested in shares for participants in the distribution reinvestment plan.
• · The record date is May 31, 2026 (5:00 PM Eastern time) and payment date is on or about June 12, 2026.

29-05-2026

Maravai LifeSciences Holdings, Inc. held its 2026 Annual Meeting on May 26, 2026, with a quorum of 236,082,968 shares present. Shareholders elected three directors (Bernd Brust, Gregory T. Lucier, Luke Marker) to three-year terms, ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026, and approved non-binding advisory say-on-pay compensation. All proposals passed with majority support, though Proposal 1 director elections saw approximately 9-11% of votes withheld against each nominee, indicating modest but notable dissent.

• · Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026 with 234,492,897 votes for, 1,246,939 against, 343,132 abstentions
• · Non-binding advisory say-on-pay proposal received 200,054,156.49 votes for, 312,439 abstentions, and 33,258,969.51 broker non-votes
• · Director Bernd Brust received 182,998,545 votes for and 19,825,453.49 withheld (9.8% withheld), Gregory T. Lucier received 179,514,826 for and 23,309,172.49 withheld (11.5% withheld), Luke Marker received 182,239,834 for and 20,584,164.49 withheld (10.2% withheld)
• · Record date for the annual meeting was March 27, 2026
• · Company has dual-class share structure with Class A and Class B common stock

29-05-2026

Apollo Commercial Real Estate Finance, Inc. (ARI) filed a DEF 14A proxy statement for the 2026 Annual Meeting, recommending shareholders vote FOR the ratification of Deloitte & Touche LLP as independent auditor for fiscal 2026 and FOR the advisory approval of named executive officer compensation (say-on-pay). The company is externally managed by ACREFI Management, LLC and has no employees; named executive officers do not receive cash compensation from ARI but are eligible for equity awards under the 2024 Equity Incentive Plan. The company's board held eight meetings during 2025 and all directors attended at least 75% of meetings. In 2025 a Special Committee was formed to review the sale of the commercial real estate loan portfolio to Athene Holding Ltd.

• · The company has no employees; it is managed externally by ACREFI Management, LLC under a management agreement dated April 24, 2026.
• · Named executive officers (including CFO Anastasia Mironova) do not receive cash compensation from ARI; CFO compensation is reimbursed to the Manager based on percentage of time spent on ARI affairs.
• · The Audit Committee recommended ratification of Deloitte & Touche LLP as independent auditor for fiscal 2026; all audit and tax fees were pre-approved by the Committee.
• · In 2025 there were no Audit-Related Fees incurred; tax fees and other fees (related to SEC filings and due diligence) were disclosed.
• · A Special Committee of the board was formed in 2025 to review the sale of the commercial real estate loan portfolio to Athene Holding Ltd.

29-05-2026

Castle Biosciences held its 2026 annual meeting on May 28, 2026, where stockholders elected three Class I directors (Ellen Goldberg, Miles D. Harrison, Tiffany P. Olson) and ratified KPMG LLP as independent auditor for fiscal 2026. All four proposals passed, including advisory approval of executive compensation and the non-employee director compensation policy. However, director Tiffany P. Olson received a notable 36.3% withhold vote, indicating some shareholder dissent.

• · Broker non-votes totaled 2,415,788 on all director elections and on proposals 3 and 4.
• · Proposal 2 (ratification of KPMG) had no broker non-votes, with 24,531,366 for, 445,666 against, and 12,187 abstain.
• · Proposal 3 (say-on-pay) received 21,280,180 for, 1,281,394 against, and 11,857 abstain.
• · Proposal 4 (non-employee director compensation) received 21,394,330 for, 1,130,133 against, and 48,968 abstain.

29-05-2026

Triumph Financial, Inc. announced a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock (equivalent to $0.44525 per depositary share). The dividend is payable on June 30, 2026 to shareholders of record on June 15, 2026. This filing contains no performance metrics or period-over-period comparisons.

29-05-2026

Ellington Financial Inc. held its 2026 Annual Meeting on May 28, 2026, where stockholders elected six directors, approved executive compensation on an advisory basis, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026, and approved the adoption of the 2026 Equity Incentive Plan. All proposals passed with strong support, though the say-on-pay vote had 3.3 million against and 0.8 million abstentions, and the Equity Incentive Plan had 2.8 million against and 0.9 million abstentions.

• · Broker non-votes totaled approximately 33.1 million shares on all proposals except the auditor ratification, which had no broker non-votes as it was considered routine.
• · The auditor ratification received 90.2 million votes for, 0.9 million against, and 0.7 million abstentions.
• · Director Stephen J. Dannhauser received the lowest 'for' votes among directors at 48.4 million, with 10.3 million withheld.
• · The Equity Incentive Plan was approved with 55.0 million for, 2.8 million against, and 0.9 million abstentions.

29-05-2026

Coastal Financial Corporation held its 2026 annual meeting on May 27, 2026, with 91% of voting power represented. All director nominees were elected, Baker Tilly US, LLP was ratified as auditor, and the advisory vote on executive compensation was approved. However, director Steven D. Hovde received a nearly tied vote (6,374,067 for vs. 6,372,171 withheld), indicating significant shareholder dissent.

• · The meeting had 13,853,559 shares represented, constituting a quorum.
• · Director Steven D. Hovde received 6,374,067 votes for and 6,372,171 withheld, a near 50/50 split.
• · Baker Tilly US, LLP was ratified as auditor with 13,810,457 votes for, 41,938 against, and 1,162 abstentions.
• · The advisory vote on executive compensation passed with 12,261,568 for, 344,062 against, and 140,608 abstentions.
• · There were 1,107,321 broker non-votes on director elections and the compensation proposal.

29-05-2026

Citius Oncology, Inc. filed an S-3 registration statement to register up to 32,931,482 shares of common stock for resale by selling stockholders, including shares underlying warrants and a conversion option. The company is not in compliance with Nasdaq's minimum bid price rule and has until October 19, 2026, to regain compliance. While the company may receive up to approximately $26.5 million in gross proceeds if all warrants are exercised for cash, it will not receive any proceeds from the resale of shares by selling stockholders, and the substantial number of shares offered (35.4% of outstanding shares) could depress the stock price.

• · The company received a Nasdaq deficiency notice on April 22, 2026, for non-compliance with the $1.00 minimum bid price rule, with a 180-day cure period ending October 19, 2026.
• · If not compliant by October 19, 2026, the company may be eligible for an additional 180-day compliance period if it meets other listing standards and intends to effect a reverse stock split.
• · The company has never paid dividends and does not anticipate paying any for the foreseeable future.
• · The company's common stock is traded on the Nasdaq Capital Market under the symbol CTOR.
• · The company's address is 11 Commerce Drive, 1st Floor, Cranford, New Jersey 07016.
• · The company will incur all costs associated with the registration statement and prospectus.
• · The warrants may be exercised on a cashless basis under certain conditions, in which case the company would receive no proceeds.

29-05-2026

Scienture Holdings, Inc. (SCNX) announced the resignation of CFO Eric Sherb on May 26, 2026, for personal reasons, with no dispute or disagreement with the company. Dr. Narasimhan Mani, age 51, who has served as a director and Co-CEO and President since May 2025, was appointed Interim CFO effective the same day. Dr. Mani brings over 25 years of pharmaceutical industry experience, including financial roles at Johnson & Johnson and Amneal Pharmaceuticals, and holds an MBA from Columbia Business School.

• · Dr. Mani has served as a director and Co-CEO and President of the Company since May 2025.
• · Dr. Mani holds a B.Pharm (Hons.) from BITS, Pilani (1995), M.S. in Analytical Chemistry from the University of Oklahoma (1998), Ph.D. in Pharmaceutics from the University of Georgia (2003), and an MBA in Finance and Marketing from Columbia Business School (2008).
• · Dr. Mani is a recipient of the 2021 Outstanding 50 Asian Americans in Business Award.
• · Dr. Mani serves on the board of Corsair Pharma, Inc. and is an invited member of the Executives-in-Residence at New Rhein Healthcare Investors.
• · Dr. Mani's employment continues under his existing employment agreement, as amended, previously disclosed in an 8-K filed on October 24, 2025.

29-05-2026

CID Holdco, Inc. completed a third closing under its Note Purchase Agreement with White Lion Capital, issuing a $287,500 senior secured convertible note for $230,000 in cash (20% OID) to fund scheduled payments to J.J. Astor & Co. Simultaneously, the company implemented a temporary furlough of all employees effective May 25, 2026, while its CEO, CFO, CTO, and Chief Revenue Officer voluntarily reduced or deferred their salaries to preserve liquidity. The company faces significant financial strain, with no assurance the furlough will not materially impact operations or revenues.

• · The note matures on the six-month anniversary of the issue date (approximately November 29, 2026).
• · Interest for the first six months accrues immediately and is guaranteed.
• · The note is a second senior secured obligation, behind a first priority lien held by J.J. Astor & Co.
• · Upon an event of default, the conversion price drops to $0.01 per share.
• · The company may prepay the note at any time without the holder's consent.
• · The company's Chief Strategy Officer also agreed to defer his salary during the furlough period.
• · A small number of independent contractors (primarily in India) continue to service customers and core initiatives.
• · The company cannot predict the duration of the furlough and may recall employees based on operational needs and capital availability.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

29-05-2026

Octave Specialty Group Inc. held its 2026 Annual Meeting on May 28, 2026, with 81% of outstanding shares represented. All seven director nominees were elected, and shareholders approved the advisory vote on executive compensation, the ratification of Ernst & Young as auditor, and the 2026 Incentive Compensation Plan. However, the advisory vote on executive compensation and the incentive plan approval each received significant opposition, with over 8 million and 10 million votes against, respectively.

• · The advisory vote on executive compensation received 19,180,354 votes for, 8,212,127 against, and 1,798,844 abstained.
• · The 2026 Incentive Compensation Plan was approved with 17,334,060 votes for, 10,059,380 against, and 1,797,885 abstained.
• · Ratification of Ernst & Young as auditor passed overwhelmingly with 34,213,342 votes for, 136,126 against, and 2,329,888 abstained.
• · Broker non-votes totaled 7,488,031 on all director elections and the advisory compensation and incentive plan votes.

29-05-2026

Skye Bioscience, Inc. filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State, effective May 28, 2026. The amendment increases the authorized capital stock from an unspecified prior amount to 300,200,000 shares (300,000,000 common shares and 200,000 preferred shares), approved by 58.63% of voting shareholders. This filing reflects a significant capital structure change, likely to support future financing or strategic initiatives.

• · The amendment was filed under NRS 78.385 and 78.390 (after issuance of stock).
• · The par value of both common and preferred stock is $0.001 per share.
• · The effective date of the amendment is May 28, 2026.
• · The filing does not specify the prior authorized share count, so the exact increase cannot be determined.

29-05-2026

TuHURA Biosciences drew $1.7M on May 26, 2026 from its $50M revolving credit facility with Parkview Holdings One LLC, with the funds intended for general corporate purposes. The loan matures on April 21, 2031. The filing notes risks that remaining facility may be insufficient to fund operations and development programs as anticipated, and that conditions to further drawdowns may not be met.

• · Loan agreement initially entered on April 21, 2026, described in a prior 8-K filed on April 22, 2026.
• · The credit facility matures on April 21, 2031.
• · Funds from this draw are for general corporate purposes.
• · Risks include potential inability to satisfy drawdown conditions or maintain compliance, and potential conflicts of interest as the lender is an affiliate of the company's largest stockholder.
• · Filing signed by CFO Dan Dearborn on May 29, 2026.

29-05-2026

iSpecimen Inc. held its reconvened 2025 Annual Meeting on May 29, 2026, with a quorum of 2,979,059 shares (35.14% of eligible shares). Shareholders elected Arphing (Tommy) Lee as a Class I director, ratified Bush & Associates CPA LLC as independent auditor, and approved the 2025 Stock Incentive Plan. However, broker non-votes were high (2,266,267) on the director election and stock plan, indicating significant retail shareholder absence.

• · The meeting was a reconvened 2025 Annual Meeting, originally scheduled earlier but adjourned.
• · Record date for the meeting was November 3, 2025.
• · Broker non-votes were 2,266,267 on both the director election and the stock plan proposal, representing about 76% of the quorum.
• · The auditor ratification proposal had no broker non-votes as it is considered a routine matter.
• · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

29-05-2026

KeyCorp filed an 8-K on May 29, 2026, announcing the posting of an investor presentation to its website for use in discussions with investors and analysts. The filing is a Regulation FD disclosure and does not contain any financial results or material operational updates.

• · The investor presentation is attached as Exhibit 99.1 and can be accessed via KeyCorp's Investor Relations page at www.key.com/ir.
• · The information in Item 7.01 and Exhibit 99.1 is not deemed 'filed' under the Securities Exchange Act of 1934 and is not incorporated by reference into other KeyCorp filings.

29-05-2026

Cingulate Inc. filed a DEFA14A on May 29, 2026, submitting definitive additional proxy materials under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee is required and does not contain specific financial figures or operational updates.

• · Filing type is DEFA14A (definitive additional proxy materials).
• · Filed by the registrant (Cingulate Inc.), not by another party.
• · No fee required for this filing.

29-05-2026

Coca-Cola Europacific Partners plc (CCEP) held its Annual General Meeting (AGM) on May 29, 2026, where all 31 resolutions were passed. Shareholder support was overwhelmingly high, with most resolutions receiving over 98% of votes cast. However, two director re-elections (Manolo Arroyo and José Ignacio Comenge) received significant opposition, with only 87.77% and 87.64% 'For' votes respectively, and the waiver of mandatory offer provisions (Resolution 25) passed with a relatively low 75.39% support from independent shareholders.

• · Resolution 25 (waiver of mandatory offer provisions) received only 75.39% 'For' votes from independent shareholders, with 24.61% against and 171,440,796 votes withheld.
• · Resolutions 7 and 9 (re-election of Manolo Arroyo and José Ignacio Comenge) saw notable opposition at 12.23% and 12.36% 'Against' respectively.
• · All other director elections and re-elections received over 98% support, with several at 99.9%.
• · The reappointment and remuneration of the auditor (Resolutions 21 and 22) passed with 99.89% and 99.99% support respectively.
• · Authority to purchase own shares on and off market (Resolutions 29 and 30) each passed with 99.21% support.

29-05-2026

On May 28, 2026, the Board of Directors of Science Applications International Corp (SAIC) declared a regular quarterly cash dividend of $0.37 per share, payable on July 24, 2026, to stockholders of record on July 10, 2026. This filing serves as the official notification of the dividend declaration and provides the associated press release. The dividend amount and timeline are consistent with SAIC's ongoing shareholder return program.

• · The dividend was declared under Item 8.01 (Other Events) and is accompanied by a press release furnished as Exhibit 99.1.
• · Record date for the dividend is July 10, 2026, and payment date is July 24, 2026.
• · The Company is incorporated in Delaware with fiscal year ending January 30, 2026 (most recent fiscal year noted in header context).

29-05-2026

Krane Financial Solutions LLC filed its 13F-HR for the quarter ended March 31, 2026, reporting total holdings of approximately $147.1 million across 48 positions. The portfolio is heavily weighted toward ETFs, with the top three holdings being iShares Russell 1000 Growth ETF ($13.9M), SPDR Gold Shares ($13.1M), and iShares Russell Mid-Cap ETF ($12.9M). No period-over-period comparisons are available in this initial filing, so performance trends cannot be assessed.

• · The portfolio is concentrated in ETFs, with the top 10 holdings accounting for approximately $100.5 million (68% of total value).
• · The largest single-stock holding is Apple Inc. at $5.53 million (3.8% of portfolio).
• · Gold exposure via SPDR Gold Shares is the second-largest position at $13.07 million.
• · International exposure includes iShares MSCI EAFE ETF ($5.54M), Vanguard FTSE Emerging Markets ETF ($5.49M), and Vanguard FTSE Developed Markets ETF ($4.42M).
• · A notable small-cap holding is VivoPower PLC (new shares) with a market value of $470,856 across 204,720 shares.
• · The filing was signed by Justin Krane, President, on May 29, 2026.

29-05-2026

BD has resumed U.S. shipments of ChloraPrep™ after voluntarily placing the product on ship hold on May 6, 2026, to conduct additional final release testing in response to an FDA Warning Letter for its El Paso facility. All additional testing has been acceptable to date, and no patient safety signals have been identified. The company continues to address the Warning Letter, and risks remain as described in its recent SEC filings.

• · The ship hold was voluntarily initiated on May 6, 2026.
• · The hold was placed in response to the FDA Warning Letter for the El Paso manufacturing facility.
• · Shipment of ChloraPrep™ has resumed; PurPrep™ status not explicitly stated as resumed.
• · No patient safety signals have been identified.
• · The company references its Form 10-Q for the period ended March 31, 2026, for details on the Warning Letter and associated risks.

29-05-2026

Quantum X Labs Inc. (formerly Viewbix Inc., ticker QXL) announced on May 28, 2026 the launch of a neutral-atom quantum computer with over 50 physical qubits. The company also set a target to reach a 'thousands qubit milestone' by the end of H1 2027. This is a technology milestone announcement with no financial details disclosed.

• · The company changed its name from Viewbix Inc. to Quantum X Labs Inc.
• · Ticker symbol is now QXL, listed on the Nasdaq Capital Market.
• · The target is 'thousands qubit milestone' by end of H1 2027.
• · The filing does not include any financial data, revenue, or profit figures.
• · No comparison with prior performance is provided.

29-05-2026

Cellectar Biosciences, Inc. filed an S-1/A registration statement with the SEC on May 29, 2026, to register securities for an IPO. The filing includes exhibits related to the company's charter, bylaws, stock plans, warrants, and material contracts. No financial data or offering details are provided in this excerpt.

• · The registration statement is filed under Registration No. 333-296036.
• · The filing includes exhibits for multiple series of preferred stock and warrants (Series D, E, Tranche A/B, Series I/II, etc.).
• · The company has amended its certificate of incorporation multiple times, most recently on June 25, 2025.
• · The filing incorporates by reference annual reports filed under Section 13(a) or 15(d) of the Exchange Act.

29-05-2026

First Financial Bancorp. held its 2026 Annual Meeting on May 26, 2026, where shareholders approved the 2026 Stock Plan, ratified Crowe LLP as auditor, elected all ten director nominees, and approved advisory executive compensation. The meeting had strong shareholder turnout of 89.71% of eligible shares, but notable withhold votes were cast against directors Maribeth S. Rahe (2.75M) and Claude E. Davis (1.55M), indicating some shareholder dissent.

• · The 2026 Stock Plan expires on May 26, 2036 and is administered by the Compensation Committee.
• · Auditor ratification received 93,734,321 votes for, 365,776 against, and 32,132 abstentions.
• · Advisory 'say on pay' vote passed with 82,796,507 for, 1,198,027 against, and 290,102 abstentions.
• · Director Maribeth S. Rahe received the highest number of withheld votes at 2,753,199 (3.3% of votes cast).
• · Director Andre T. Porter received the fewest withheld votes at 301,850.

29-05-2026

Principal Exchange-Traded Funds filed a DEFA14A on May 29, 2026, reminding shareholders of the Principal Capital Appreciation Select ETF about a special meeting on June 25, 2026 to vote on changing the Fund's sub-classification from "diversified" to "non-diversified" under the Investment Company Act of 1940. The company provides voting instructions by phone, internet, or mail.

• · The special meeting is scheduled for June 25, 2026.
• · Shareholders can vote by phone at 1-888-569-8137 weekdays 10 a.m. to 11 p.m. Eastern time.
• · Sodali Fund Solutions is acting as proxy solicitor and may contact shareholders to assist in voting.

29-05-2026

NewHold Investment Corp IV filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net loss of $38,000 and total assets of $281,000, up from $91,000 at year-end 2025. The company had no cash on hand and an accumulated deficit of $85,000, while shareholder's deficit widened to $60,000 from $22,000. The increase in assets was driven by deferred offering costs, but the company remains in a pre-operational stage with no revenue.

• · No Class A ordinary shares were issued or outstanding as of March 31, 2026.
• · The company had no cash at the beginning or end of the quarter.
• · Deferred offering costs increased from $83,000 to $277,000, funded through a related party loan of $86,000 and accrued offering costs of $185,000.
• · General and administrative expenses for the quarter were $38,000.
• · Basic and diluted net loss per Class B ordinary share was $(0.01).
• · The company has 479,000,000 authorized Class A ordinary shares and 20,000,000 authorized Class B ordinary shares, all with $0.0001 par value.

29-05-2026

Financial Investors Trust filed a DEFA14A (definitive additional proxy materials) on May 29, 2026, announcing that the shareholder meeting for the Emerald Finance and Banking Innovation Fund has been adjourned and will reconvene on July 2, 2026. At the reconvened meeting, shareholders will vote on a proposed reorganization of the Fund into the Emerald Banking & Finance Evolution Fund, a series of a new trust. The filing provides no financial figures or performance data, only procedural updates regarding the proxy vote.

• · The shareholder meeting was adjourned and will reconvene on July 2, 2026 at 10:00 a.m. Mountain Time at 1290 Broadway, Suite 1000, Denver, CO 80203.
• · Shareholders of record as of July 11, 2025 are eligible to vote on the reorganization.
• · The supplement updates the Prospectus and SAI dated August 28, 2025.

29-05-2026

Principal Credit Real Estate Income Trust declared May 2026 distributions of $0.1350 per share across all share classes (Class I, F-S, F-I, E, A). Class F-S shares have a net distribution of $0.1203 after a $0.0147 shareholder servicing fee, while other classes receive the full gross amount. The distributions are payable on June 18, 2026, to shareholders of record as of May 29, 2026.

• · The gross distribution amount of $0.1350 per share is for the month of May 2026.
• · Distributions will be paid in cash or reinvested for shareholders in the distribution reinvestment plan.
• · Record date for distributions is May 29, 2026; payment date is on or about June 18, 2026.

29-05-2026

Kennedy Lewis Capital Company reported an aggregate NAV of $744.0M ($20.12–$20.16/share across three share classes) as of April 30, 2026. The company's total investment portfolio fair value reached $1.11B, while it has raised $664.1M in cumulative proceeds from its public and private offerings. The company continues its continuous offering of up to $2.0B in shares, with public offering proceeds of $350.6M and private offering proceeds of $313.5M, but no Class S or D shares have been sold in the private offering, indicating limited demand for those share classes in that channel.

• · NAV per share was nearly identical across classes: Class I $20.16, Class S $20.12, Class D $20.16.
• · No Class S or Class D shares have been issued in the private offering, and no Class S or D private offering proceeds have been raised.
• · Public offering consideration was heavily concentrated in Class I shares ($349.2M of the $350.6M public total), with only ~$1.27M in Class S and $0.15M in Class D.
• · The company has raised $664.1M of the $2.0B maximum offering amount to date.

29-05-2026

Wintrust Financial Corporation held its 2026 Annual Meeting on May 28, 2026, where shareholders elected all 12 director nominees, approved the advisory (non-binding) proposal on 2025 executive compensation, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026. All proposals passed with strong majority support, though the ratification of the auditor received a notable 4.25 million votes against, indicating some shareholder dissent.

• · All 12 director nominees were elected with votes for ranging from 55,192,285 (Peter D. Crist) to 58,398,500 (Timothy S. Crane).
• · Peter D. Crist received the highest number of votes against (3,343,601) among director nominees.
• · The advisory vote on 2025 executive compensation had 56,857,769 votes for, 1,623,123 against, and 75,966 abstentions.
• · Ratification of Ernst & Young LLP as independent auditor had 57,552,404 votes for, 4,249,760 against, and 27,921 abstentions, with no broker non-votes.
• · Broker non-votes were 3,273,227 for all director elections and the executive compensation proposal, but zero for the auditor ratification.

29-05-2026

Orrstown Financial Services announced the redemption of its $31,000,000 outstanding 4.5% Fixed-to-Floating Rate Subordinated Notes due 2030 on June 30, 2026, at 100% of principal plus accrued interest. Separately, the company disclosed a third-party vendor cybersecurity incident that exposed sensitive personal information of certain customers, though the company's own systems were not compromised and no material financial impact is expected.

• · The Notes were assumed by the Company upon completion of its merger with Codorus Valley Bancorp, Inc. on July 1, 2024.
• · The cybersecurity incident was discovered via notice from a third-party vendor on May 21, 2026.
• · The company is one of a number of organizations affected by this vendor's cybersecurity incident.
• · The company's information systems and networks have not been accessed, compromised, or affected by the incident.
• · There is currently no indication that customer information has been misused.
• · Impacted customers will be offered credit monitoring services.
• · The company does not currently anticipate a material impact on financial condition or results of operations from the incident.

29-05-2026

TAP Real Estate Technologies, Inc. (formerly HUMBL, INC.) entered into an Option to Purchase Agreement on March 24, 2026, with Wasatch Springs Management Holdings, LLC for the potential acquisition of the Zermatt Resort in Midway, Utah. The initial 60-day option period was extended by an additional 90 days via an addendum signed on May 22, 2026. No financial terms or purchase price were disclosed in the filing.

• · The option agreement was originally entered into on March 24, 2026.
• · The addendum extending the option was signed on May 22, 2026.
• · The registrant's name changed from HUMBL, INC. to TAP Real Estate Technologies, Inc. (ticker: RWAX, traded on OTCID).
• · The company is an emerging growth company and has not elected the extended transition period for complying with new financial accounting standards.